Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CDH20 Biologics Sequence Review Report 2026: Cadherin-20 Similarity and Patent-Risk Signals
8 min read
CDH20 Biologics Sequence Review Report 2026: Cadherin-20 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH19 Biologics Sequence Review Report 2026: Cadherin-19 Similarity and Patent-Risk Signals
8 min read
CDH19 Biologics Sequence Review Report 2026: Cadherin-19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH22 Biologics Sequence Review Report 2026: Cadherin-22 Similarity and Patent-Risk Signals
8 min read
CDH22 Biologics Sequence Review Report 2026: Cadherin-22 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH17 Biologics Sequence Review Report 2026: Cadherin-17 Similarity and Patent-Risk Signals
8 min read
CDH17 Biologics Sequence Review Report 2026: Cadherin-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH18 Biologics Sequence Review Report 2026: Cadherin-18 Similarity and Patent-Risk Signals
8 min read
CDH18 Biologics Sequence Review Report 2026: Cadherin-18 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH18 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH16 Biologics Sequence Review Report 2026: Cadherin-16 Similarity and Patent-Risk Signals
8 min read
CDH16 Biologics Sequence Review Report 2026: Cadherin-16 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH15 Biologics Sequence Review Report 2026: Cadherin-15 Similarity and Patent-Risk Signals
8 min read
CDH15 Biologics Sequence Review Report 2026: Cadherin-15 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH15 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH12 Biologics Sequence Review Report 2026: Cadherin-12 Similarity and Patent-Risk Signals
8 min read
CDH12 Biologics Sequence Review Report 2026: Cadherin-12 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH10 Biologics Sequence Review Report 2026: Cadherin-10 Similarity and Patent-Risk Signals
8 min read
CDH10 Biologics Sequence Review Report 2026: Cadherin-10 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH13 Biologics Sequence Review Report 2026: Cadherin-13 Similarity and Patent-Risk Signals
8 min read
CDH13 Biologics Sequence Review Report 2026: Cadherin-13 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH11 Biologics Sequence Review Report 2026: Cadherin-11 Similarity and Patent-Risk Signals
8 min read
CDH11 Biologics Sequence Review Report 2026: Cadherin-11 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDH1 Biologics Sequence Review Report 2026: Cadherin-1 Similarity and Patent-Risk Signals
8 min read
CDH1 Biologics Sequence Review Report 2026: Cadherin-1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →